KalVista Pharmaceuticals Acquired by Chiesi | Healthcare M&A Deal

Chiesi has completed the acquisition of KalVista Pharmaceuticals, a pharmacy business in New York, for $1.9 billion. Chiesi acquisitions focus on rare disease therapeutics, and KalVista Pharmaceuticals develops and commercializes EKTERLY (sebetralstat), an oral, as-needed therapy for hereditary angioedema (HAE). Chiesi acquires KalVista Pharmaceuticals to strengthen its US commercial infrastructure and expand access to effective, affordable treatments for patients with HAE. The merger acquisition is a strategic acquisition by a strategic buyer, with a $27 per share all-cash public offering to Nasdaq-listed KalVista shareholders, subject to regulatory approvals and minimum tender conditions, and is expected to close in Q3 2026.